Baird Capital has acquired a stake in London-based Prescient Healthcare Group, a product strategy consultancy for the biopharmaceutical sector. No financial terms were disclosed. In conjunction with the deal, Baird Capital’s Andrew Ferguson and John DiGiovanni have been added to Prescient’s board of directors while Nick Edwards will become chairman.
LONDON, 27 July 2017 – Baird Capital, the direct investment arm of Robert W. Baird & Co., announced today that it has acquired an interest in Prescient Healthcare Group (Prescient). Prescient is a leading product strategy consultancy to the global biopharmaceutical industry. As part of the transaction, Baird Capital Partner Andrew Ferguson and Principal John DiGiovanni will join the Prescient board of directors. Nick Edwards, founder and former Chairman of Kinapse, will chair the board.
Founded in 2007, Prescient is headquartered in London and has offices in the US, India and China. The business provides product strategy services to help its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients, customers and shareholders. Prescient partners with many of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharma organisations.
“The Prescient team has built a fantastic business that day-in and day-out supports blue-chip clients with the insight and analysis they need to make business-critical decisions. Prescient’s commitment to delivering a top-quality service has resulted in a loyal and fast-growing customer base. The market for the company’s services is set to continue to grow strongly as biopharmaceutical companies seek to develop and market products in a cost- and time-effective way. Our investment and global resources will help further accelerate Prescient’s growth and we look forward to partnering with the team in an exciting future for the business”, said Andrew Ferguson, Partner at Baird Capital.
Jamie Denison-Pender, Prescient CEO, commented “We are thrilled to be partnering with Baird Capital, which has an extensive track record of helping people-based businesses grow and knowledge of the healthcare sector. Baird’s global resources, experience in scaling professional services organisations and focus on talent development will be critical as Prescient enters its next stage of growth. Prescient has an incredibly loyal customer base and this deal will enable us to continue enhancing the level and value of service we offer our clients.”
About Prescient Healthcare Group
Prescient Healthcare Group is a specialty biopharmaceutical product strategy and decision support consultancy that helps clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients, customers and shareholders. With offices in London, New York, San Francisco, New Delhi and Beijing, it enhances the value of its clients’ products, making sure they resonate with customers and stand out from the competition. Prescient’s mission is to optimally shape new product, brand and mature brand planning strategies. For more information, please visit www.prescienthg.com.
About Baird Capital
Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 300 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. For more information, please visit www.BairdCapital.com.